The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LIX.y

Histoplamosis (reactivation)

Publications

Durand ML, Lin DT, Juliano AF, Sadow PM

Case records of the Massachusetts General Hospital. Case 32-2014. A 78-year-old woman with chronic sore throat and a tonsillar mass.

The New England journal of medicine 2014 Oct 16;371;1535-43 — 2014 Oct 16 — 1535-43

Pinheiro Bdo V, Delgado Ade A, Chebli JM

Hepatitis and pneumonitis during adalimumab therapy in Crohn disease: mind the histoplasmosis!

Arquivos de gastroenterologia 2014 Jan-Mar;51;73-6 — 2014 Jan-Mar — 73-6

Olson TC, Bongartz T, Crowson CS, Roberts GD, Orenstein R, Matteson EL

Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009.

BMC infectious diseases 2011 May 23;11;145 — 2011 May 23 — 145

Jain VV, Evans T, Peterson MW

Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area.

Respiratory medicine 2006 Jul;100;1291-3 — 2006 Jul — 1291-3

Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB, Wheat LJ, Twigg HL

Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.

American journal of respiratory and critical care medicine 2003 May 01;167;1279-82 — 2003 May 01 — 1279-82

Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN, Braun MM

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.

Arthritis and rheumatism 2002 Oct;46;2565-70 — 2002 Oct — 2565-70

Nakelchik M, Mangino JE

Reactivation of histoplasmosis after treatment with infliximab.

The American journal of medicine 2002 Jan;112;78 — 2002 Jan — 78